Presenta tati tion to: o: 1 Our Our Missi ssion To m make g - - PowerPoint PPT Presentation

Presenta tati tion to:

• :

1

Our Our Missi ssion

To m make g geno enomic t tes esting readily dily availa ilable ble at pric ices everyon yone can affor

• rd

2

WGA is is a an adv dvis isor to to the e lif ife ins nsur urance a e and nd em employee ee ben enef efit broker erage i e ind

• ndustry. We

We are re com

• mpos
• sed of

f both h sea easoned ned i ins nsur uranc nceexec ecut utives ves an and scie ienti tists ts with h geno enomicback ackgrounds

• Genomic Science
• Product Opportunities
• Global Suppliers
• Marketplace Intelligence
• New Developments

Who

• We

We Are re We a e asp spire to be e the e global so source for trust sted ed advi vice rega garding: g:

3

A. . Greig Woodri dring Chairman of

• f th

the Board rd Tom Wambe berg rg Chief ief E Executive ive Offic icer er Willia lliam A

• A. Rope
• per

Chief ief Finan ancial al Offic icer er Mar ark A.

• A. Winham

Chief ef S Scien ientifi ific & Oper erating O Offi fficer Erin Stalke ker VP, B Busi sine ness ss D Developme ment nt Lynnet ette e Bates VP, B Busi sine ness ss D Developme ment nt

Our Ex Execu ecutive T e Team eam

• Dr. P

Phili ilip S Smalle lley Chief ief M Medic ical Director Nic ick B Bella llanca Senio ior VP, B Busin ines ess D Deve velopment Jame mes M s M. Benso son Lead D d Direc ector

• r

4

5

Wamb mberg Genomi

• mic Advisor

sors i s is a a trust sted source o

• n G

Genom

• mics

Wamberg's 's scien ientific a and m nd medic edical t tea eam c cont ntinually eva valuates pr provi vide ders to assur ure t e the m e most u up-to to-date ate appropriate ate t testing

6

1

• Uncover genetic factors that increase disease risk
• Guide optimal medication selection and dosage for

improved outcomes

• Highlight risk of inherited diseases
• Provide insight into rare diseases

Ge Genomi

• mic Progr
• grams

ams

7

The R e Real eality of Can Cancer cer

• 40% chance of developing cancer in our lifetime.
• Cancer is the cause of over 22% of all deaths
• A major cause of disability and long term care claims.
• 28% of cancers are initially misdiagnosed.*

8

Identif tifie ies most t effectiv ive treatment optio ions Prov

• vides th

the foll llowin ing valuable ble infor

• rma

mation

• n:
• Information that confirms t

ms the accu curacy cy o

• f diagno

nosi sis

• Information that highlights a

s addi ditional o

• ptions f

for r potentiall lly m more e effec ective t e treatmen ents, for example:

• Immunotherapy
• Targeted therapies
• Clinical trial participation

The C e Cancer cer G Guar ardian an™ P ™ Program am™

Cancer Genomic Profiling Tests are typically NOT Covered by Medicare, Medicaid and insurance companies.

COST RANGE UP TO $7500

(Some Patients need more than one test)

Many people have difficulty affording this testing at the

• nset of cancer because of high

deductibles and co-pays.

9

Gen enomic M Med edici cine in the R e Real eal W World: : ‘Ho Hope’ a and ‘ d ‘Hy Hype pe’ Success Stori ries

It’s the story of Nicholas Volker, a then 4-year-old boy who had undergone more than 100 surgeries in his lifetime, including a colon removal, and basically lived in a hospital as doctors tried to identify the rare disorders he was dying from. It was 2009, and his doctors, having tried everything else, turned to something virtually untried, DNA sequencing, to see if they could identify gene mutations leading to his disorders. “They found he had two changes in his DNA, and they figured he would respond well to a bone marrow transplant. Now he lives a normal life,” Kucherlapati said. Forbes Magazine called him “The First Child Saved by DNA Sequencing.

• Chris Orchard, Harvard T.H. Chan School of Public Health

10

STUDY 1 1

Clinical study of overall survival data for 805 patients with (NSCL) non small-cell lung cancer:

• For the 131 patients who received a targeted

therapy based off patient’s genetic profile at some time during their treatment, the median

• verall survival was 31.8 months.
• In contrast, of the 482 patients who received

cytotoxic chemotherapy (most common type of cancer treatment), the median overall survival was 12.7 months and was 5.1 months for the 192 patients who received only supportive care.

*AmericanSocietyofClinicalOncology,Volume13/Issue2/February2017inJournalofOncologyPractice *-Gutierrez, Martin E., Kelly Choi, Richard B. Lanman, Edward J. Licitra, Stanley M. Skrypczak, Ruth PeBenito, Tommy Wu, Srikesh Arunajadai, Sukhi Kaur, Harry Harper, Andrew L. Pecora, Eric V. Schultz, and Stuart L. Goldberg. “Genomic Profiling of Advanced

Non–SmallCellLungCancerinCommunitySettings:GapsandOpportunities.”GenomicProfilingofAdvancedNon– SmallCellLungCancerinCommunitySettings:GapsandOpportunities- ScienceDirect. ElsevierInc.,13Apr.2017.Web.21July 2017. http://www.sciencedirect.com/science/article/pii/S1525730417301092

Cancer r Genomic ic P Profilin ing C g Clinic ical l Study dy

11

Surv urvival Ra Rates s

31.8 31.8 mont nths versu sus s 12.7 12.7 mont nths

• r

r 5.1 5.1 mont nths

* In some cases complete remission

Ex Excl clusive e LifeMa Mark rk Cancer er G Guar ardian an™ P ™ Program am

• Produce

cers can can offer C Can ance cer G Guar ardian™ t to A All NEW p poli licyholde lders

• First year progr

gram charge rges waived ved for poli licyholde lder & & child ldren

• On t

the f first poli licy a anniv iversary, p partic ticipa ipants ts may contin tinue t the p program v via direct b t billi illing f from WGA

• Program c

charges rges r range f e from $ $8-15 p 15 per partic ticipa ipant p t per m month th – age e banded ed rates es

12

Cancer cer G Guar ardian an™ P ™ Program am Advan antag ages es

Fo For T The P Produce cer

• Exclusive LifeMark product to be used to drive sales and client

retention

• Enhance client engagement
• Competitive advantage at point of sale at no cost to producer.
• Will provide your clients with a valuable tool that has the ability to

save their lives

• Producer will be viewed as a partner in supporting their clients

long and healthy life

13

The S e Soci ciet etal al V Value

Together we strive to continue to find ways to make genomic testing easy and

• accessible. This will lead to more testing that will create more data and more cures.

+ +

Mor More

Testin ting

Mor More Data ta Mor More Car are Paths hs

= Mor

• re Cur

ures

14

15

Publ blic Re Rela lations

LifeMark and its agency members will be th the f fir irst nati tional f fir irm to offer Cancer Guardian™ to its policyholders. Being the first is NEWS!

• Industry announcement at the Society of Actuaries conference in March 2018
• Full PR and Marketing campaign provided by Wamberg Genomic + Lead

generation program provided for agents

• National press coverage campaign

16

Prog

• gram E

Execut ution n - Fo Four Eas Easy S Steps

Step 1 1. . Agent provides new policyholder printed or digital Cancer Guardian ™ Program Guide at time of life policy placement. Step 2 2. . Agency file of eligible policyholders sent to WGA weekly. Step 3 3. . WGA will reach out to anyone that has not registered their Cancer Guardian™ Program online.

• Digital
• Direct Mail
• Phone

17

Prog

• gram E

Execut ution n – Fo Four Eas Easy S Steps

Step 4 4. . Completion of Program Participation Registration – online or via phone support

• Ability to add spouse and dependent children
• Confirmation e-mail once registration is complete

with electronic version of Program I.D. card.

• Custom Printed I.D. cards will be made available

when requested at program registration.

18

The e LifeM eMar ark Partn tners rship ip

• Innovative product offerings to differentiate your team

and drive sales

• Industry recognition – tools for recruiting
• Dedicated implementation, account management, and

client support

• Full enrollment and communication capabilities
• Ongoing Product offerings and engagement

19

The e LifeM eMar ark Partn tners rship ip

• Extending Life
• Extending Relationships
• Making a Difference

20

Questions & Next Steps

Thank you

21

Our P r Produ ducts ts

22

Whole G

• le Genom
• me S

e Sequen ence ce & & Repor

• rt

Whole Genome Sequencing (WGx) provides the most comprehensive view of the genome, all 6.4 billion nucleotides. Whole E

• le Exom
• me S

e Sequence & e & Repor

• rt

Whole Exome Sequence (WEx) focuses on the genes that express proteins in a genome (2%). WEx has largely contributed to the identification of new disease-causing genes. Cancer G r Guardi dian™ ( ™ (CGx) Sequencing the cancer tumor confirms the diagnosis and provides information about the mutations that contribute to tumor progression. Pharma macogenomi mics ( s (PGx) By sequencing DNA we can test an individuals comprehensive drug compatibility which helps to bridge the gap between diagnosis and effective treatment. Stem C m Cell Banking Stem cells gathered at birth can currently be used in the treatment of more than 70 serious and life-threatening diseases. Health Intelli lligence Club (HIx Ix) Lifetime connectivity with one’s DNA is the goal of the Club. Once a policyholder has been sequenced, they will have the most comprehensive view of their genome. Through membership in the Club policyholders